Argenx stock gets fresh VYVGART data before Q3 results

Published on 10/05/2026 at 22:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock was last at USD 912.87 on October 5, 2026, as new VYVGART data broadened the treatment story. Q2 revenue reached USD 1.54 billion.

Redaktionelles Börsenfoto: Leuchtende Handelsdisplays mit grünen Aufwärtskurven im Biotech-Sektor, verschwommener Handelssaal im Hintergrund, Atmosphäre des Finanzjournalismus — Argenx NL0010832176 leuchtende Handelsbildschirme an der Euronext zeigen steigende grüne Kurven für Biotech-Aktien, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) was last at USD 912.87 on Nasdaq on October 5, 2026, while the company’s newest VYVGART data broadened its clinical story across neuromuscular diseases. The stock’s 52-week range is USD 661.85 to USD 1,072.75, leaving the latest price 14.9 percent below the high.

VYVGART data widen the story

In a release dated September 29, 2026, GlobeNewswire reported that argenx would present clinical, long-term and real-world data at meetings held through October 2, 2026. The presentations covered VYVGART in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, plus pipeline candidates empasiprubart and adimanebart.

The most decision-relevant figure came from a real-world analysis of more than 1,100 U.S. patients. Patients treated within one year of diagnosis recorded a mean MG-ADL reduction of 4.7 points during the first three months, compared with 3.5 points among patients treated more than three years after diagnosis, according to GlobeNewswire.

Quarterly numbers set a high bar

argenx’s second-quarter performance also gives the data a commercial benchmark. MarketBeat reported Q2 2026 revenue of USD 1.54 billion versus a USD 1.45 billion consensus estimate. Reported EPS was USD 7.32, ahead of the USD 5.86 consensus by USD 1.46, giving investors a quantified measure of the earnings cushion behind the pipeline narrative.

The same report listed 17 Buy ratings, two Strong Buy ratings and five Holds among 24 covering firms. Its average 12-month price target was USD 1,158.61, which places the target 26.9 percent above the October 5 price of USD 912.87. The comparison matters because the stock is also 14.9 percent below its 52-week high, leaving valuation and execution as competing reference points.

Q3 results arrive October 21

argenx is scheduled to release third-quarter 2026 results on October 21, 2026, according to MarketScreener. That report will provide the next direct test of whether VYVGART demand can sustain the USD 1.54 billion quarterly revenue base while the company expands into additional autoimmune indications.

Nasdaq valuation remains substantial

argenx was last at USD 912.87 on Nasdaq on October 5, 2026, down 0.69 percent from the prior session. The company’s market capitalization was USD 56.8 billion, and trading volume reached 322,123 shares, putting the clinical data against a large and actively followed biotechnology valuation.